阿托伐它汀治疗糖尿病肾病35例分析

目的:探讨阿托伐它汀对糖尿病肾病的疗效和抗感染机制。方法:选择门诊及住院糖尿病肾病(diabetic nephropathy,DN)64例,随机分为对照组29例和治疗组35例。对照组予以常规治疗(严格控制血糖、血压的基础上加用卡托普利或缬沙坦),治疗组在对照组的基础上加用阿托伐它汀40 mg,每天1次。两组治疗6个月后,比较血浆C反应蛋白(CRP)、尿白蛋白排泄率(UAER)、血浆肌酐(SCr)变化。结果:阿托伐它汀能显著降低DN患者空腹血浆CRP、SCr水平及UAER,与对照组差异均有统计学意义(P<0.01)。结论:阿托伐它汀能显著降低DN患者UAER及炎症反应,改善肾功能。

Atorvastatin in treatment of diabetic nephropathy: analysis of 35 cases

Objective： To investigate the efficacy and anti-inflammatory mechanism of atorvastatin in treatment of diabetic nephropathy. Methods：Sixty four cases of diabetic nephropathy （DN） in our hospital were randomly divided into treatment group 35 cases and control group 29 cases. The control group were only administered the conventional therapy （ ACEI or ARB）, and the treatment group were given atorvastatin 40 mg,once a day in addition to the routine therapy. The plasma C-reactive protein （CRP）, urinary albumin excretion rate （UAER） ,plasma creatinine （SCr） ,and other indicators were compared between the two groups six months after treatment. Results：Atorvastatin significant decreased the CRP, SCr and UAER in the patients with diabetic nephropathy（P 〈 0.01 ）. Conclusions：Atorvastatin may obviously reduce the UAER and the inflammatory response of DN,and improve the renal function of the patients with diabetic nephropathy,